<DOC>
	<DOCNO>NCT02762643</DOCNO>
	<brief_summary>A randomized , open-label , crossover , Phase I clinical trial compare pharmacokinetics DP-R213 ( Raloxifenel Cholecaliferol fix dose combination ) comparison component administer alone healthy male volunteer .</brief_summary>
	<brief_title>DP-R213 Pharmacokinetics Study</brief_title>
	<detailed_description />
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>IBW Â±20 % sign informed consent form prior study participation Clinically significant disease Previously donate whole blood within 2 month component blood within 1 month Clinically significant allergic disease Taken IP trial within 3 month An impossible one participate clinical trial investigator 's decision include laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>DP-R213</keyword>
</DOC>